Predicting the Risk of Failed Trial Without Catheter Following Rezum™ Therapy

BPH treatment is moving to a new era of personalized care. Minimally invasive surgical therapies such as REZUM^™ are filling the gap between oral and conventional surgical treatment. Patient information and selection are keys for tailor-made treatment.

After REZUM™, patients are discharged with a Foley catheter but the optimal duration of catheterisation remains unclear. Our findings highlighted 2 important messages:

10% of patients experienced an early unsuccessful catheter removal, but that doesn't impact short-term functional outcomes.
PVR>120mL is a significant risk factor for longer catheterization. Size of the prostate/number of punctures may also lead to longer catheterization.

Written by: Mathieu Coscarella, Urologist, Department of Urology, Ambroise Paré Hospital, Université Libre de Bruxelles, Mons, Belgium, Department of Urology, Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre Bruxelles, Brussels, Belgium

Read the Abstract

Login